CencoraWBO:ABC +1.27%68 Forward PE Ratio is 15.60 as of Jul. 09, 2026. GuruFocus rates WBO:ABC with a GF Score™ of 68/100 and a GF Value™ of €256.66 (Fairly Valued). The stock has 1 warning sign investors should review. Among 51 Medical Distribution companies, Cencora ranks worse than 66.67% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Cencora Forward PE Ratio Related Terms
Cencora Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Cencora's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cencora Forward PE Ratio Chart
Cencora Annual Data
Trend
2023-09
2024-09
2025-09
Forward PE Ratio
13.95
14.95
17.41
Cencora Quarterly Data
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
14.14
13.72
15.08
13.95
15.82
18.90
15.24
14.95
15.42
17.16
16.51
17.41
18.92
18.18
WBO:ABC vs CAH, MCK, HSIC: Forward PE Ratio Comparison
For the Medical Distribution subindustry, Cencora's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cencora Forward PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cencora's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Cencora's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Cencora (WBO:ABC) has a Forward PE Ratio of 15.60 as of Jul. 09, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Cencora and its competitors. According to the industry distribution chart, Cencora ranks #34 out of 51 companies in the Medical Distribution industry, placing it in the top 66.7%.
Is Cencora's Forward PE Ratio too high?
Cencora's current Forward PE Ratio is 15.60. The Medical Distribution industry median Forward PE Ratio is 14.32. Cencora's value of 15.60 is 8.9% above this industry median. Based on the distribution chart, Cencora ranks #34 out of 51 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Cencora has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's Forward PE Ratio compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #34 out of 51 companies for Forward PE Ratio. This places Cencora in the lower half of its industry. The industry median Forward PE Ratio is 14.32. Cencora's value of 15.60 is 8.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Distribution company?
The median Forward PE Ratio among Medical Distribution companies is 14.32, based on 51 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cencora's current Forward PE Ratio of 15.60 is 8.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Cencora and its competitors. For the Medical Distribution industry, the median Forward PE Ratio is 14.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cencora's current Forward PE Ratio is 15.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €256.66, compared to a current price of €271.70 — trading 5.9% above its estimated fair value. The current Forward PE Ratio is 15.60 and 8.9% above the Medical Distribution industry median of 14.32. Cencora's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Cencora (WBO:ABC), the current Forward PE Ratio is 15.60 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (WBO:ABC) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be overvalued.
The current stock price of €271.70 is trading 5.9% above its estimated GF Value™ of €256.66.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for WBO:ABC:
Forward PE Ratio: 15.60
GF Value™: €256.66 vs. price of €271.70 (5.9% above fair value)
Industry Position: 8.9% above the Medical Distribution median (#34 of 51)
No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
68GF Score
Get the complete analysis for WBO:ABC
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ABC has been successfully added to your 